Randomized, Parallel, Double-blind, Placebo Controlled, Study in Men to Assess the Influence of Aronox on Parameters Associated With Recovery Following Muscle Damaging Exercise
Randomized, Parallel, Double-blind, Placebo Controlled, Study in Men to Assess the Influence of Aronox on Parameters Associated With Recovery Following Muscle Damaging Exercise
A randomized, double blind, counterbalanced, placebo controlled independent groups design. Prior to the visit, participants will be given a participant information sheet to inform of the procedure and requirements and undergo initial screening via email or telephone to ascertain suitability to participate. Stature, body mass, blood pressure and heart rate will be assessed. Participants will then be familiarized with the performance tests (MVC, vertical jump and sprint performance) and randomized to an investigational product group (2 groups: Aronox vs placebo; 1:1 allocation). The first investigational dose will be administered in the laboratory and participants will be given a 4-week supply of the investigational product to take in the morning with breakfast. Participants will also be asked to keep a food and activity diary for the 3 days preceding the baseline visit and for the duration of the damaging-recovery protocol.
Following this supplementation period (28 days), participants will be asked to return to the lab in a fed (not less than 2 hours prior to the visit) and hydrated state. Participants will also be asked to abstain from strenuous exercise and caffeine for 24 h prior to each lab visit. Stature, body mass, blood pressure and heart rate will be assessed. This will be followed by baseline assessment of muscle damage which will consist of visual analogue scales to assess lower limb muscle soreness (DOMS); pain pressure threshold and baseline measures of functional performance (maximal voluntary contraction, vertical jump performance and sprint performance) and limb girth. Furthermore, a blood sample will be taken to analyze creatine kinase (index of muscle damage). This will be followed by a strenuous bout of exercise designed to cause muscle damage comprising of 100 drop jumps from a 0.6 m platform at a rate of 1 jump every 10 seconds. A short rest will be provided after every 20 jumps. Each jump is performed by the participant stepping from the platform and landing two-footed on the floor and descending quickly to ~90° and 'explosively jumping upward with maximum effort. This model for muscle damage has been used on numerous occasions in the literature and has been used with great success in our own laboratory. Participants will then return to the lab at 24, 48 and 72 h post damaging protocol where muscle damage measures will be repeated to assess the level of recovery between the groups.
A randomized, double blind, counterbalanced, placebo controlled independent groups design. Prior to the visit, participants will be given a participant information sheet to inform of the procedure and requirements and undergo initial screening via email or telephone to ascertain suitability to participate. If interested parties wish to participate, then they will be invited for a familiarisation visit, where they will:
Stature, body mass, blood pressure and heart rate will be assessed. Participants will then be familiarized with the performance tests (MVC, vertical jump and sprint performance) and randomized to an investigational product group (2 groups: Aronox vs placebo; 1:1 allocation). The first investigational dose will be administered in the laboratory and participants will be given a 4-week supply of the investigational product to take in the morning with breakfast. Participants will also be asked to keep a food and activity diary for the 3 days preceding the baseline visit and for the duration of the damaging-recovery protocol.
Following this supplementation period (28 days), participants will be asked to return to the lab in a fed (not less than 2 hours prior to the visit) and hydrated state. Participants will also be asked to abstain from strenuous exercise and caffeine for 24 h prior to each lab visit. Stature, body mass, blood pressure and heart rate will be assessed. This will be followed by baseline assessment of muscle damage which will consist of visual analogue scales to assess lower limb muscle soreness (DOMS); pain pressure threshold and baseline measures of functional performance (maximal voluntary contraction, vertical jump performance and sprint performance) and limb girth. Furthermore, a blood sample will be taken to analyze creatine kinase (index of muscle damage). This will be followed by a strenuous bout of exercise designed to cause muscle damage comprising of 100 drop jumps from a 0.6 m platform at a rate of 1 jump every 10 seconds. A short rest will be provided after every 20 jumps. Each jump is performed by the participant stepping from the platform and landing two-footed on the floor and descending quickly to ~90° and 'explosively jumping upward with maximum effort. This model for muscle damage has been used on numerous occasions in the literature and has been used with great success in our own laboratory. Participants will then return to the lab at 24, 48 and 72 h post damaging protocol where muscle damage measures will be repeated to assess the level of recovery between the groups.
Exercise protocol details Muscle damage will be induced using a drop jump protocol our laboratory has used previously. It consists of 100 drop jumps performed 10 seconds apart with a 2-minute rest period provided every 20 jumps. Each jump will be conducted from a 0.6 m high box; upon landing, participants descend to a ~90º knee angle before performing a maximal effort vertical jump.
Passive muscle soreness will be reported on a 200 mm visual analogue scale and muscle site-specific soreness will be assessed as pressure pain threshold (PPT) with a handheld algometer (N2). Measurements were taken with participants lying supine; pressure was applied continuously at a rate of ~10 N cm-2∙s-1 until a pressure of ~40 N cm-2∙s-1 is achieved on the muscle belly; whereupon the participant will report muscle soreness on the aforementioned visual analogue scale.
Limb girth will be measured at the mid-thigh to examine limb swelling. This will be determined by identifying the midpoint between the inguinal crease and the superior border of the patella the right leg whilst the participant remained standing in anatomical zero. The location will be marked with permanent marker to ensure consistency on subsequent days.
A venous blood sample will then taken to examine creatine kinase (CK) concentrations to provide evidence that muscle damage has occurred.
Maximal isometric voluntary contractions (MIVCs) performed using a portable strain gauge (MIE Medical Research Ltd., Leeds, UK), will be used to examine strength loss and recovery. The peak value from 3 maximal contractions (separated by 60 seconds) will be used for analysis. In addition, counter movement jumps (CMJ) will be examined with an optical system to measure jump height in cm. With hands on their hips, participants will descend into a ~90° squat and jump vertically with maximal effort. The average of 3 maximal jumps (separated by 30 seconds) will be used for analysis. Participants will complete a single maximal effort 30 m sprint where sprint time will be recorded. The sprint will be initiated from a line 30 cm behind the start line in order to prevent false triggering of the timing gates (Brower, Utah, USA). In addition to the aforementioned measures that will be repeated at 24, 48 and 72 h, a perceived recovery questionnaire to assess more qualitative aspects of the intervention on recovery from the damaging protocol will be completed.
Supplementation and dietary control Following group allocation, participants will be provided with aronia (Aronox® ) or placebo (PLA) supplementation and instructed to consume 500mg of the investigational product. The PLA will consist of 95% maltodextrin with 5% artificial dyes (red lake and blue lake). The 500mg of Aronox is fortified with maltodextrin in order to provide 200 mg of polyphenol in total. Aronia consumption has shown no safety issues when used as an ingredient in dietary supplements or as a study drug in clinical trials by adults at dose levels ranging from 150 to 300 mg of extract per day for 14 days up to 2 months (Broncel et al., 2010; Naruszewicz et al., 2007).
Participants will be instructed not to consume the supplement on the day of initial assessment and consume the supplement after each laboratory visit as previous research (Bitsch et al. 2004; Kurilich et al. 2005) has demonstrated that systemic anthocyanin bioavailability increases to a peak between 1-2 hours post-ingestion. In addition, training logs will be kept to examine differences in training volume between groups and also general health log to record illness or consumption of any pharma during the supplementation period.
Data analysis
All data will be expressed as means ± SD, and statistical significance will be set at P < 0.05 prior to analyses. Differences in participant group characteristics, training history, and dietary intake were analysed using Student t-tests. Nutritics dietary analysis software (Nutritics LTD, Dublin, Ireland) will be used to analyse participant's food diaries. Dependent variables (MIVC, CMJ, VAS, and all blood indices) will be analysed using a mixed model ANOVA with 2 independent group levels (Aronex vs. PLA) and 4 repeated measures time points (pre, 24,48,72 h). If the ANOVA indicates a significant interaction effect (drink × time), Fisher LSD post hoc analysis will be performed to locate the significant differences. Homogeneity of variance will be checked with Mauchly's test of sphericity, and in the event of a significant result, GreenhouseGeisser adjustments will be used. All data will be analysed using IBM SPSS Statistics 22 for Windows (Surrey, UK).
Inclusion Criteria:
Exclusion Criteria: